查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1718070

新抗原癌症疫苗市場按新抗原類型、治療標靶、疫苗平台、給藥途徑和最終用戶分類－2025-2030 年全球預測

Neoantigen Cancer Vaccine Market by Neoantigen Type, Therapeutic Target, Vaccine Platform, Administration Route, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計新抗原癌症疫苗市場規模到 2024 年將達到 3.7866 億美元，到 2025 年將達到 4.3455 億美元，到 2030 年將達到 8.7678 億美元，複合年成長率為 15.01%。

主要市場統計數據
基準年2024年 3.7866億美元
預計2025年 4.3455億美元
預測年份 2030 8.7678億美元
複合年成長率（%） 15.01%

新抗原癌症疫苗利用人體免疫系統的潛力來針對腫瘤特異性抗原，成為對抗癌症的一種有前途的方法。這種創新治療策略建立在個人化治療的概念之上，從而解決每個腫瘤獨特的突變特徵。該領域的發展得益於基因序列測定和生物資訊學的突破，使得人們能夠更精確地識別引發免疫反應的新抗原。因此，臨床醫生和研究人員越來越有能力設計出刺激免疫系統識別和消滅以前逃避標準治療方法的癌細胞的疫苗。

最近的進展不僅提高了我們對腫瘤免疫學的理解，而且為將個人化治療納入標準腫瘤通訊協定鋪平了道路。由於有望改善患者的治療效果，同時降低全身毒性，因此該方法成為傳統治療方法的一種有吸引力的替代方法。此外，科學界越來越關注個人化和共用的新抗原，凸顯了這些疫苗的變革潛力。本執行摘要詳細概況了目前的市場動態、顛覆性技術轉變、細分見解，並闡明了新抗原癌症疫苗領域的未來發展藍圖。

重新定義新抗原疫苗格局的變革性轉變

在研究、技術和臨床應用的一系列變革性轉變的推動下，新抗原癌症疫苗領域正在發生深刻的變化。早期臨床前的成功現已進入臨床評估的多個階段，反映了全球將科學突破轉化為實際治療方法的努力。人工智慧與先進生物資訊工具的融合，使得快速識別潛在的新抗原標靶成為可能，提高了疫苗開發的準確性和速度。同時，不斷發展的法律規範正在適應個人化治療帶來的獨特挑戰，促進更快、更嚴格的核准流程。

同時，學術機構、生物技術和製藥公司之間的合作正透過合作研究加速創新。這種多學科方法正在重新定義傳統的治療模式，並使人們更全面地了解癌症的免疫反應機制。隨著研究人員破解腫瘤遺傳學和免疫逃脫之間的複雜相互作用，可以提高疫苗效力的新途徑也變得越來越明顯。此外，從 RNA 到基於胜肽的疫苗平台的技術進步正在進一步擴大治療選擇。這種轉型轉變不僅有望改善治療結果，而且還將推動更具適應性和彈性的市場生態系統，以更好地滿足世界各地癌症患者的多樣化需求。

新抗原癌症疫苗市場更深入的細分洞察

對新抗原癌症疫苗市場的全面分析揭示了基於多維度穩健細分的見解。在考慮新抗原類型時，市場分析區分了個人化新抗原和共用新抗原。個人化新抗原關注免疫逃脫和體細胞突變的細微差別，這是療效和患者特異性客製化的關鍵指標。在共用新抗原領域，親和性肽和常見的腫瘤突變已被強調，凸顯了不僅在不同患者特徵中重複出現而且在疫苗設計中具有廣泛潛在應用的標靶的價值。

依治療目標進一步細分，突顯了以免疫查核點阻斷為中心的身臨其境型策略與針對腫瘤新抗原的策略之間的差異。免疫查核點路徑進一步細分，重點分析CTLA-4抑制劑和PD-1抑制劑。將腫瘤新抗原細分為突變形式和非突變形式可以進行更詳細的分析，並提供對潛在疫苗反應的洞察。另一個重要的細分層面來自於疫苗平台的多樣性。市場分為基於細胞的疫苗、基於 DNA 的疫苗、基於胜肽的疫苗和基於 RNA 的疫苗。在這些類別中，基於細胞的方法正在深入研究樹突狀細胞和 T 細胞疫苗，而 DNA 平台正在探索環狀和基於質體的策略。同樣，胜肽平台涉及長肽和合成肽，而基於 RNA 的技術則按傳統 mRNA 疫苗和下一代 RNA 平台進行排名。它還研究了皮內、靜脈、口服和皮下等給藥途徑，以及癌症治療中心、醫院和研究機構等最終用戶。這些細分見解可作為策略性市場投資和有針對性的研究舉措的基礎。

目錄

第1章 引言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 癌症疾病的日益流行要求深入研究個人化癌症疫苗解決方案。
      • 意識提升
      • 政府對癌症研究和發展舉措的支持政策和資金
    • 限制因素
      • 對新抗原癌症疫苗嚴重副作用的擔憂
    • 機會
      • 生技公司之間的策略合作加速了新抗原疫苗研究的進展
      • 創新技術進步推動新抗原癌症疫苗的潛在應用
    • 任務
      • 個人化疫苗核准的嚴格法規環境和合規性
  • 市場區隔分析
    • 新抗原類型：針對個別腫瘤特異性突變的個人化新抗原癌症疫苗的需求日益成長
    • 最終使用者：癌症治療中心擴大新抗原疫苗的使用，以提高個人化治療的有效性
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社會
    • 技術的
    • 合法的
    • 環境

6. 新抗原癌症疫苗市場（以新抗原類型）

  • 個人化新抗原
    • 免疫逃脫突變
    • 體細胞突變
  • 共用新抗原
    • 親和性肽
    • 常見腫瘤突變

7. 新抗原癌症疫苗市場治療標靶

  • 免疫查核點抑制
    • CTLA-4抑制劑
    • PD-1抑制劑
  • 腫瘤新抗原
    • 突變的新抗原
    • 未突變的新抗原

8. 新抗原癌症疫苗市場疫苗平台

  • 細胞疫苗
    • 樹突細胞疫苗
    • T細胞疫苗
  • DNA疫苗
    • 環狀DNA平台
    • 質體DNA疫苗
  • 胜肽類疫苗
    • 長胜肽
    • 合成胜肽
  • 基於RNA的疫苗
    • mRNA疫苗
    • 下一代RNA平台

9. 新抗原癌症疫苗市場（依給藥途徑）

  • 皮內
  • 靜脈
  • 口服
  • 皮下

第 10 章 新抗原癌症疫苗市場（依最終使用者）

  • 癌症治療中心
  • 醫院
  • 研究機構

11.美洲新抗原癌症疫苗市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

12. 亞太地區新抗原癌症疫苗市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

13. 歐洲、中東和非洲新抗原癌症疫苗市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭情境分析
  • 戰略分析與建議

公司名單

  • Agenus Inc.
  • AstraZeneca PLC
  • Avidea Technologies
  • Ayala Pharmaceuticals, Inc.
  • BioLineRx Ltd.
  • BioNTech SE
  • BioVaxys Technology Corp.
  • Brightpath Biotherapeutics Co., Ltd.
  • CureVac NV
  • Elicio Therapeutics Inc
  • F. Hoffmann-La Roche Ltd.
  • Geneos Therapeutics, Inc. by Inovio Pharmaceuticals, Inc.
  • Genocea Biosciences Inc
  • GenScript Biotech Corporation
  • Gilead Sciences, Inc.
  • Gritstone bio, Inc.
  • Immunomic Therapeutics, Inc.
  • ISA Pharmaceuticals BV
  • Medigene AG
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Neophore Limited
  • Nouscom AG
  • Nykode Therapeutics ASA
  • OSE Immunotherapeutics
  • Takis Srl
Product Code: MRR-5C6F41F5AFED

The Neoantigen Cancer Vaccine Market was valued at USD 378.66 million in 2024 and is projected to grow to USD 434.55 million in 2025, with a CAGR of 15.01%, reaching USD 876.78 million by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 378.66 million
Estimated Year [2025] USD 434.55 million
Forecast Year [2030] USD 876.78 million
CAGR (%) 15.01%

Neoantigen cancer vaccines are emerging as a promising approach in the fight against cancer by harnessing the potential of the body's immune system to target tumor-specific antigens. This innovative therapeutic strategy is built around the concept of tailoring treatments to individual patients, thereby addressing the unique mutational profile of each tumor. The evolution of this field has been driven by breakthroughs in genomic sequencing and bioinformatics, enabling a more precise identification of neoantigens that can provoke an immune response. As a result, clinicians and researchers are increasingly able to design vaccines that stimulate the immune system to recognize and eliminate cancer cells, which have previously evaded standard treatment methods.

Recent advancements have not only enhanced our understanding of tumor immunology but have also paved the way for integrating personalized therapies into standard oncology protocols. The promise of improving patient outcomes while mitigating systemic toxicity makes this approach an attractive alternative to conventional treatments. Moreover, the scientific community's intensified focus on both personalized and shared neoantigens has underscored the transformative potential of these vaccines. This executive summary provides a detailed overview of current market dynamics, transformative technological shifts, and segmentation insights, building a clear picture of the roadmap ahead in the neoantigen cancer vaccine arena.

Transformative Shifts Redefining the Neoantigen Vaccine Landscape

The landscape of neoantigen cancer vaccines is undergoing profound change, driven by a series of transformative shifts in research, technology, and clinical application. Early preclinical success has now transitioned into multiple stages of clinical evaluation, reflecting a concerted global effort to translate scientific breakthroughs into tangible therapies. The integration of artificial intelligence and advanced bioinformatics tools has enabled a more rapid identification of potential neoantigen targets, enhancing both the precision and speed of vaccine development. In parallel, evolving regulatory frameworks are adapting to the unique challenges posed by personalized treatments, thereby facilitating faster, yet rigorous, approval processes.

Simultaneously, partnerships among academic institutions, biotech firms, and pharmaceutical companies have accelerated innovation through collaborative research efforts. This multidisciplinary approach is redefining traditional treatment paradigms, leading to a more holistic understanding of immune response mechanisms in cancer. As researchers decipher the complex interplay between tumor genetics and immune evasion, they are also uncovering novel pathways that can be targeted to enhance the efficacy of vaccines. Additionally, technological advancements in vaccine platforms, ranging from RNA to peptide-based modalities, are further expanding treatment options. These transformative shifts not only promise improved outcomes but also drive a more adaptable and resilient market ecosystem that is poised to address the diverse needs of oncology patients worldwide.

Deep Dive Into Segmentation Insights for the Neoantigen Cancer Vaccine Market

A comprehensive analysis of the neoantigen cancer vaccine market reveals insights that are rooted in robust segmentation across multiple dimensions. In examining the neoantigen type, the market analysis distinguishes between personalized neoantigens and shared neoantigens. For personalized neoantigens, the focus intensifies on the nuances of immune escape mutations versus somatic mutations, which provide critical benchmarks for efficacy and patient-specific customization. In the realm of shared neoantigens, attention is directed to affinity peptides and common tumor mutations, emphasizing the value of targets that are not only recurrent across different patient profiles but also hold potential for broad applicability in vaccine design.

Further segmentation by therapeutic target underscores a bifurcation between immersive strategies centered on immune checkpoint blockade and those targeting tumor neoantigens. The immune checkpoint pathway is further refined with analyses centered on CTLA-4 and PD-1 inhibitors. The subdivision of tumor neoantigens into mutated versus non-mutated variants offers additional granularity, affording insights into potential vaccine responsiveness. Another important layer of segmentation is derived from the diversity of the vaccine platforms available. The market is segmented into cell-based vaccines, DNA-based vaccines, peptide-based vaccines, and RNA-based vaccines. Within these categories, cell-based approaches delve into dendritic cell vaccines and T-cell vaccines, whereas DNA platforms explore both circular and plasmid-based strategies. Likewise, peptide platforms address long and synthetic peptides, and RNA-based technologies are ranked by traditional mRNA vaccines alongside next-generation RNA platforms. Consideration is also given to the route of administration-spanning intradermal, intravenous, oral, and subcutaneous methods-and the end user, which includes cancer treatment centers, hospitals, and research institutes. These segmentation insights collectively form the cornerstone for strategic market investments and targeted research initiatives.

Based on Neoantigen Type, market is studied across Personalized Neoantigens and Shared Neoantigens. The Personalized Neoantigens is further studied across Immune Escape Mutations and Somatic Mutations. The Shared Neoantigens is further studied across Affinity Peptides and Common Tumor Mutations.

Based on Therapeutic Target, market is studied across Immune Checkpoint Blockade and Tumor Neoantigens. The Immune Checkpoint Blockade is further studied across CTLA-4 Inhibitors and PD-1 Inhibitors. The Tumor Neoantigens is further studied across Mutated Neoantigens and Non-Mutated Neoantigens.

Based on Vaccine Platform, market is studied across Cell-Based Vaccines, DNA-Based Vaccines, Peptide-Based Vaccines, and RNA-Based Vaccines. The Cell-Based Vaccines is further studied across Dendritic Cell Vaccines and T-Cell Vaccines. The DNA-Based Vaccines is further studied across Circular DNA Platforms and Plasmid DNA Vaccines. The Peptide-Based Vaccines is further studied across Long Peptides and Synthetic Peptides. The RNA-Based Vaccines is further studied across mRNA Vaccines and Next-Gen RNA Platforms.

Based on Administration Route, market is studied across Intradermal, Intravenous, Oral, and Subcutaneous.

Based on End User, market is studied across Cancer Treatment Centers, Hospitals, and Research Institutes.

Key Regional Insights Highlighting Global Market Variations

A regional analysis reveals distinct trends and growth potentials across key global markets. In the Americas, robust research infrastructures and established pharmaceutical markets have accelerated the clinical adoption of neoantigen vaccines. This region benefits from extensive clinical trials and significant investments in biotechnology, fostering an environment where personalized treatments are rapidly integrated into treatment protocols.

In Europe, the evolution of stringent yet adaptive regulatory frameworks, combined with a focus on precision medicine, is driving the uptake of innovative vaccine therapies. Markets in the Middle East and Africa, though emerging, are beginning to carve out niches as partnerships with international research bodies encourage technology transfer and skill development. Meanwhile, the Asia-Pacific region is experiencing a surge in market activity attributed to rapid economic growth and increased healthcare spending. The diverse regulatory landscapes and the high prevalence of cancer cases in this region underscore the strategic importance of harnessing advanced vaccine platforms and localized manufacturing capabilities. These regional insights illustrate not only varying levels of technological readiness and market maturity but also reveal opportunities for expanding the reach of neoantigen cancer vaccines into new and promising territories.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Analysis of Key Market Players Driving Innovation in Neoantigen Vaccines

The competitive landscape within the neoantigen cancer vaccine market is marked by the active involvement of several leading organizations that are driving innovation and market growth. Prominent firms such as Agenus Inc., AstraZeneca PLC, and Avidea Technologies are at the forefront of developing next-generation immunotherapies through robust research and development initiatives. Several other companies, including Ayala Pharmaceuticals, Inc. and BioLineRx Ltd., are also making significant strides by exploring novel vaccine formulations that offer improved immunogenic profiles. The rise of BioNTech SE and BioVaxys Technology Corp. as key innovators reflects the industry's shift towards rapidly scalable vaccination platforms coupled with high precision targeting.

Additional contributions from Brightpath Biotherapeutics Co., Ltd., CureVac N.V., and Elicio Therapeutics Inc. illustrate a diversified approach to vaccine development, balancing both traditional and cutting-edge delivery systems. F. Hoffmann-La Roche Ltd. and Geneos Therapeutics, Inc. by Inovio Pharmaceuticals, Inc. further amplify market innovation by leveraging their expansive global networks and multidisciplinary research teams. Emerging companies like Genocea Biosciences Inc. and GenScript Biotech Corporation are challenging long-held treatment paradigms with breakthrough research, while established firms such as Gilead Sciences, Inc. and Merck & Co., Inc. continue to expand their portfolios with strategic investments. The presence of Gritstone bio, Inc., Immunomic Therapeutics, Inc., and ISA Pharmaceuticals B.V. underscores the competitive dynamism in this sector, paralleled by Medigene AG, Moderna, Inc., and Neophore Limited stepping in to address diversified market needs. Companies such as Nouscom AG, Nykode Therapeutics ASA, OSE Immunotherapeutics, and Takis S.r.l. bring specialized skills and insights that help to balance market offerings, ensuring that innovations are both scientifically robust and clinically impactful. This broad spectrum of players is collectively advancing the field while contributing to a vibrant, competitive environment.

The report delves into recent significant developments in the Neoantigen Cancer Vaccine Market, highlighting leading vendors and their innovative profiles. These include Agenus Inc., AstraZeneca PLC, Avidea Technologies, Ayala Pharmaceuticals, Inc., BioLineRx Ltd., BioNTech SE, BioVaxys Technology Corp., Brightpath Biotherapeutics Co., Ltd., CureVac N.V., Elicio Therapeutics Inc, F. Hoffmann-La Roche Ltd., Geneos Therapeutics, Inc. by Inovio Pharmaceuticals, Inc., Genocea Biosciences Inc, GenScript Biotech Corporation, Gilead Sciences, Inc., Gritstone bio, Inc., Immunomic Therapeutics, Inc., ISA Pharmaceuticals B.V., Medigene AG, Merck & Co., Inc., Moderna, Inc., Neophore Limited, Nouscom AG, Nykode Therapeutics ASA, OSE Immunotherapeutics, and Takis S.r.l.. Strategic Recommendations for Capitalizing on Neoantigen Vaccine Opportunities

Industry leaders are encouraged to adopt a multifaceted strategy that emphasizes both innovation and collaboration. Investment in cutting-edge research and the integration of advanced bioinformatics tools are critical to stay ahead in vaccine development. Embracing modular vaccine platforms that allow rapid customization and scalability will enable stakeholders to better address the variability in tumor profiles and patient-specific needs. Strategic partnerships with academic institutions and research laboratories can further accelerate the pace of discovery, while clinical collaborations will help validate promising approaches in real-world settings. Additionally, streamlining regulatory pathways and investing in robust clinical trial designs will serve to reduce time-to-market, ensuring that breakthrough therapies reach patients without unnecessary delays. The convergence of these strategies will not only foster growth but also cement a competitive edge in the dynamic field of neoantigen cancer vaccines.

Conclusion: Charting the Future of Personalized Cancer Immunotherapy

In conclusion, the neoantigen cancer vaccine market stands at a pivotal juncture, driven by innovative scientific breakthroughs and evolving clinical technologies. The integration of personalized therapies, supported by meticulous segmentation across neoantigen types, therapeutic targets, and vaccine platforms, positions the field for transformative change. Global regional dynamics further amplify market opportunities, while a robust competitive landscape ensures continuous innovation through strategic R&D investments. As the sector advances, stakeholders will increasingly rely on data-driven insights and collaborative approaches to address complex oncological challenges. This comprehensive market review underscores the immense potential of neoantigen vaccines to reshape cancer treatment paradigms and offers a roadmap for achieving sustainable growth and improved patient outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of cancer diseases compelling robust research in personalized cancer vaccine solutions
      • 5.1.1.2. Increasing public awareness about the benefits of personalized and preventive cancer treatments
      • 5.1.1.3. Supportive government policies and funding for cancer research and development initiatives
    • 5.1.2. Restraints
      • 5.1.2.1. Concerns associated with significant side effects of neoantigen cancer vaccines
    • 5.1.3. Opportunities
      • 5.1.3.1. Strategic collaborations among biotech companies accelerating advancements in neoantigen vaccine research
      • 5.1.3.2. Innovative technological advancements boosting the potential applications of neoantigen cancer vaccines
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory environments and compliance for personalized vaccine approval
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Neoantigen Type: Increasing need for personalized neoantigen cancer vaccines to target unique mutations specific to an individual's tumor
    • 5.2.2. End User: Expanding utilization of neoantigen vaccines by cancer treatment centers for personalized treatment efficacy
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Neoantigen Cancer Vaccine Market, by Neoantigen Type

  • 6.1. Introduction
  • 6.2. Personalized Neoantigens
    • 6.2.1. Immune Escape Mutations
    • 6.2.2. Somatic Mutations
  • 6.3. Shared Neoantigens
    • 6.3.1. Affinity Peptides
    • 6.3.2. Common Tumor Mutations

7. Neoantigen Cancer Vaccine Market, by Therapeutic Target

  • 7.1. Introduction
  • 7.2. Immune Checkpoint Blockade
    • 7.2.1. CTLA-4 Inhibitors
    • 7.2.2. PD-1 Inhibitors
  • 7.3. Tumor Neoantigens
    • 7.3.1. Mutated Neoantigens
    • 7.3.2. Non-Mutated Neoantigens

8. Neoantigen Cancer Vaccine Market, by Vaccine Platform

  • 8.1. Introduction
  • 8.2. Cell-Based Vaccines
    • 8.2.1. Dendritic Cell Vaccines
    • 8.2.2. T-Cell Vaccines
  • 8.3. DNA-Based Vaccines
    • 8.3.1. Circular DNA Platforms
    • 8.3.2. Plasmid DNA Vaccines
  • 8.4. Peptide-Based Vaccines
    • 8.4.1. Long Peptides
    • 8.4.2. Synthetic Peptides
  • 8.5. RNA-Based Vaccines
    • 8.5.1. mRNA Vaccines
    • 8.5.2. Next-Gen RNA Platforms

9. Neoantigen Cancer Vaccine Market, by Administration Route

  • 9.1. Introduction
  • 9.2. Intradermal
  • 9.3. Intravenous
  • 9.4. Oral
  • 9.5. Subcutaneous

10. Neoantigen Cancer Vaccine Market, by End User

  • 10.1. Introduction
  • 10.2. Cancer Treatment Centers
  • 10.3. Hospitals
  • 10.4. Research Institutes

11. Americas Neoantigen Cancer Vaccine Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Neoantigen Cancer Vaccine Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Neoantigen Cancer Vaccine Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Everest Medicines Initiated personalized mRNA cancer vaccines with EVM16 clinical trial for neoantigen targeting
    • 14.3.2. Achilles Therapeutics and Arcturus Therapeutics to collaborate on next-generation personalized mRNA cancer vaccine research
    • 14.3.3. Transgene and NEC expand collaboration to advance TG4050 neoantigen cancer vaccine into Phase I/II trial
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Agenus Inc.
  • 2. AstraZeneca PLC
  • 3. Avidea Technologies
  • 4. Ayala Pharmaceuticals, Inc.
  • 5. BioLineRx Ltd.
  • 6. BioNTech SE
  • 7. BioVaxys Technology Corp.
  • 8. Brightpath Biotherapeutics Co., Ltd.
  • 9. CureVac N.V.
  • 10. Elicio Therapeutics Inc
  • 11. F. Hoffmann-La Roche Ltd.
  • 12. Geneos Therapeutics, Inc. by Inovio Pharmaceuticals, Inc.
  • 13. Genocea Biosciences Inc
  • 14. GenScript Biotech Corporation
  • 15. Gilead Sciences, Inc.
  • 16. Gritstone bio, Inc.
  • 17. Immunomic Therapeutics, Inc.
  • 18. ISA Pharmaceuticals B.V.
  • 19. Medigene AG
  • 20. Merck & Co., Inc.
  • 21. Moderna, Inc.
  • 22. Neophore Limited
  • 23. Nouscom AG
  • 24. Nykode Therapeutics ASA
  • 25. OSE Immunotherapeutics
  • 26. Takis S.r.l.

LIST OF FIGURES

  • FIGURE 1. NEOANTIGEN CANCER VACCINE MARKET MULTI-CURRENCY
  • FIGURE 2. NEOANTIGEN CANCER VACCINE MARKET MULTI-LANGUAGE
  • FIGURE 3. NEOANTIGEN CANCER VACCINE MARKET RESEARCH PROCESS
  • FIGURE 4. NEOANTIGEN CANCER VACCINE MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 17. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 19. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 21. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. NEOANTIGEN CANCER VACCINE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 27. NEOANTIGEN CANCER VACCINE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. NEOANTIGEN CANCER VACCINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. NEOANTIGEN CANCER VACCINE MARKET DYNAMICS
  • TABLE 7. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE ESCAPE MUTATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SOMATIC MUTATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY AFFINITY PEPTIDES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COMMON TUMOR MUTATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY MUTATED NEOANTIGENS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NON-MUTATED NEOANTIGENS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DENDRITIC CELL VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY T-CELL VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CIRCULAR DNA PLATFORMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PLASMID DNA VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY LONG PEPTIDES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SYNTHETIC PEPTIDES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY MRNA VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEXT-GEN RNA PLATFORMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY INTRADERMAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CANCER TREATMENT CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 61. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 62. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 63. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 65. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 67. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 68. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
  • TABLE 69. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
  • TABLE 70. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 71. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 72. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 73. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 74. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 75. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 76. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 77. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 78. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 80. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 81. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
  • TABLE 82. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
  • TABLE 83. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 84. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 85. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 86. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 87. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 88. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 89. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 90. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 91. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 93. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 94. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
  • TABLE 95. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
  • TABLE 96. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 97. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 98. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 99. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 100. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 101. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 102. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 103. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 104. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 106. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 107. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
  • TABLE 108. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
  • TABLE 109. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 110. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 111. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 112. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 113. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 114. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 115. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 116. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 117. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 119. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 120. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
  • TABLE 121. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
  • TABLE 122. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 123. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 124. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 125. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 126. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 127. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 128. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 129. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 130. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 145. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 147. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 148. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
  • TABLE 149. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
  • TABLE 150. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 151. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 152. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 153. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 154. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 155. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 156. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 157. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 158. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 160. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 161. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
  • TABLE 162. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
  • TABLE 163. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 164. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 165. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 166. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 167. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 168. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 169. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 170. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 171. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 173. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 174. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
  • TABLE 175. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
  • TABLE 176. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 177. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 178. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 179. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 180. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 181. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 182. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 183. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 184. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 186. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 187. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
  • TABLE 188. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
  • TABLE 189. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 190. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 191. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 192. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 193. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 194. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 195. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 196. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 197. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 199. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 200. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
  • TABLE 201. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
  • TABLE 202. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 203. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 204. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 205. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 206. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 207. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 208. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 209. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 210. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 212. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 213. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
  • TABLE 214. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
  • TABLE 215. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 216. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 217. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 218. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 219. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 220. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 221. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 222. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 223. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 225. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 226. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
  • TABLE 227. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
  • TABLE 228. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 229. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 230. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 231. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 232. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 233. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 234. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 235. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 236. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 238. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 239. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
  • TABLE 240. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
  • TABLE 241. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 242. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 243. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 244. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 245. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 246. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 247. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 248. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 249. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 250. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 251. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 252. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
  • TABLE 253. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
  • TABLE 254. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 255. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 256. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 257. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 258. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 259. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 260. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 261. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 262. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 263. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 264. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 265. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
  • TABLE 266. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
  • TABLE 267. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 268. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 269. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 270. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 271. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 272. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 273. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 274. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 275. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 276. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 277. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 278. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
  • TABLE 279. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
  • TABLE 280. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 281. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 282. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 283. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 284. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 285. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 286. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 287. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 288. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 289. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 290. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 291. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
  • TABLE 292. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
  • TABLE 293. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 294. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 295. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 296. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 297. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 298. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2030 (USD MILLION)
  • TABLE 299. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 300. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 301. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 302. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 303. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 304. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2030 (USD MILLION)
  • TABLE 305. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2030 (USD MILLION)
  • TABLE 306. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2030 (USD MILLION)
  • TABLE 307. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 308. EUROPE, MIDDLE EAST & AFRICA NE